title: [Combined treatment of voiding disorders in women with m-cholinolytic and alpha 1-adrenoblocker].
abstract: The drug spasmex (trospium chloride) having an m-cholinolytic and myotropic spasmolytic action has been used for treatment of enuresis in women with imperative voiding syndrome. Spasmex was given in combination with alpha 1-adrenoblockers to 20 women. The clinical picture was assessed with the original table. Urodynamic alterations were registered by means of home uroflowmeter. Clinical parameters improved 2 times after 4 weeks of the treatment. Mean effective capacity of the urinary bladder increased by 25%. Spasmex in combination with terasozine was well tolerated and had no side effects.
authors.forename: V V
authors.initials: VV
authors.lastname: Danilov
authors.forename: I Iu
authors.initials: IIu
authors.lastname: Vol'nykh
authors.forename: C K
authors.initials: CK
authors.lastname: Abdullaeva
authors.forename: T I
authors.initials: TI
authors.lastname: Danilova
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage*; D001561:Benzilates; D005260:Female; D006801:Humans; D008875:Middle Aged; D009662:Nortropanes / Q000008:administration & dosage*; D010276:Parasympatholytics / Q000008:administration & dosage*; D011224:Prazosin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D014463:Ultrasonography; D001743:Urinary Bladder / Q000000981:diagnostic imaging / Q000473:pathology; D014549:Urinary Incontinence / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D014563:Urodynamics / Q000187:drug effects
chemical_list: D000317:Adrenergic alpha-Antagonists; D001561:Benzilates; D009662:Nortropanes; D010276:Parasympatholytics; C003330:trospium chloride; C041226:Terazosin; D011224:Prazosin